CeriBell (NASDAQ:CBLL) Director Rebecca Robertson Sells 827 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca Robertson sold 827 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $16.67, for a total value of $13,786.09. Following the completion of the sale, the director directly owned 8,388 shares of the company’s stock, valued at $139,827.96. The trade was a 8.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CeriBell Stock Up 2.6%

NASDAQ:CBLL traded up $0.49 on Friday, hitting $19.64. The stock had a trading volume of 149,288 shares, compared to its average volume of 302,333. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75. The business’s fifty day moving average is $13.27 and its 200 day moving average is $14.40. The company has a market cap of $728.64 million, a PE ratio of -13.01 and a beta of 1.35.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. On average, equities research analysts expect that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analysts Set New Price Targets

CBLL has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Raymond James Financial started coverage on CeriBell in a research report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price target for the company. JPMorgan Chase & Co. reduced their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, TD Cowen dropped their price target on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.17.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CBLL. Tower Research Capital LLC TRC grew its stake in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the period. Ameritas Investment Partners Inc. boosted its position in CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of CeriBell in the third quarter valued at approximately $33,000. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of CeriBell by 161.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after buying an additional 3,502 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in CeriBell by 148.6% in the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares during the period.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.